IMFINZI Demonstrated Statistically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in NIAGARA Phase III Trial
July 26, 2024
July 26, 2024
WILMINGTON, Delaware, July 26 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
* * *
Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primar . . .
* * *
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
* * *
Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primar . . .